drugset / Trial / NCT00112229
Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients
Phase 1
Completed
29 enrolled
Centre Hospitalier Universitaire Vaudois
Ludwig Institute for Cancer Research · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether vaccination with tumor antigenic peptides and both CpG and Montanide adjuvants can induce an immune response in melanoma patients and to assess the safety of this vaccination.
Timeline
- Start
- 2003-04
- Primary completion
- 2011-08
- Completion
- 2012-06
Publications
- Results Speiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005 Mar;115(3):739-46. doi: 10.1172/JCI23373.
- Results Baumgaertner P, Jandus C, Rivals JP, Derre L, Lovgren T, Baitsch L, Guillaume P, Luescher IF, Berthod G, Matter M, Rufer N, Michielin O, Speiser DE. Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells. Int J Cancer. 2012 Jun 1;130(11):2607-17. doi: 10.1002/ijc.26297. Epub 2011 Aug 24.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Melan-A analog peptide | Peptide | — | — |
| Subject | Melan-A natural peptide | Peptide | — | — |
| Subject | Tyrosinase YMD peptide | Peptide | — | — |
| Background | agatolimod | Oligonucleotide (other) | — | — |
| Background | incomplete Freund's adjuvant | Other / unclassified | — | — |